Authors: Jason Y Park Kerry B Dunbar Midori Mitui Christina A Arnold Dora M LamHimlin Mark A Valasek Irene Thung Chinemerem Okwara Elizabeth Coss Byron Cryer Christopher D Doern
Publish Date: 2016/02/29
Volume: 61, Issue: 8, Pages: 2373-2380
Abstract
A multicenter retrospective cohort study for clarithromycinresistant H pylori was conducted over four academic medical centers in different geographic regions of the USA Gastric biopsy material residual from standard clinical pathologic examination was examined for clarithromycin resistance by DNA sequencing of H pylori 23S rRNAOne hundred and twentyfour cases of H pylori gastritis were examined from medical centers in four different geographic regions of the USA The overall prevalence of clarithromycin resistance was 323 range 231–458 There was no significant difference in the prevalence of clarithromycin resistance by study site gender age or race/ethnicity In a subset of 67 patients that had clinical followup data the overall prevalence of clarithromycin resistance was 313 There was a 29fold increase p = 0002 in treatment failure for cases with clarithromycin resistance 571 compared to wildtype H pylori 196 H pylori clarithromycin resistance in the USA exceeds the estimated 20 prevalence compatible with successful empiric antibiotic therapy This resistance resulted in a significant rate of treatment failure in all sites surveyed Empiric therapy in the USA should be used with caution until there is better regional or local determination of H pylori antibiotic resistance
Keywords: